Overview

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

Status:
RECRUITING

Trial end date:
2030-04-01

Target enrollment:

Participant gender:

Summary

Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy

Phase:

PHASE2

Details

Lead Sponsor:

Technische Universitt Dresden

Treatments:

Azacitidine
gilteritinib
venetoclax